Acute kidney injury post coronary angioplasty

Sachin Motiram Naik, Shubham Shukla, Jasmine Sethi, Aravind Sekar

DESCRIPTION

A elderly women in her seventh decade, hypertensive for past 10 years, had a recent episode of ST-segment elevation myocardial infarction (MI) for which she underwent percutaneous coronary angiography with stenting of left anterior descending artery. Subsequently, she was initiated on aspirin 75 mg daily, ticagrelor 90 mg daily and rosuvastatin 40 mg daily. Laboratory parameters at this time revealed serum creatinine of 95.47 µmol/L and normal lipid profile. Two weeks post this episode of MI, the patient presented with complaints of bilateral thigh pain and decreased urine output for past 7 days. She also gave history of brownish discolouration of urine a week prior, following which her urine output dropped to less than 100 mL/day (figure 1A). Current laboratory parameters revealed haemoglobin of 138 g/L, total leucocyte count of 9.9×10^9/µL and serum creatinine of 848.64 µmol/L. Ultrasound examination showed bilateral normal sized kidneys with raised cortical echogenicity. Her urine dipstick test showed positivity for blood (2+) but no erythrocytes on microscopic examination. Further, she had an elevated creatine kinase (CK) level of 38 908 U/L (reference range 0–195 U/L) and urine myoglobin of 1073 ng/mL (reference range 28–72 ng/mL). Remaining work up including antinuclear antibody (ANA), anti-neutrophil cytoplasmic antibody (ANCA), serum protein electrophoresis and hepatitis serology were negative. The patient denied taking any other drug, including indigenous or over the counter medications. A clinical diagnosis of statin induced rhabdomyolysis was considered based on muscle cramps, brown coloured urine, elevated muscle enzymes and urine dipstick/microscopy dissociation. We stopped rosuvastatin on day 2 and substituted ticagrelor with clopidogrel. The patient was initiated on haemodialysis via a tunneled cuffed internal jugular catheter in view of oliguria. Gradually over next 1 week, the patient had improvement in the form of increase in urine output and declining CK levels. She was discharged after 1 week with serum creatinine of 530 µmol/L and haemodialysis was stopped. However, in view of non-resolving acute kidney injury (AKI), a kidney biopsy was done at week 4 that showed evidence of pigmented casts in the tubules and tubular injury with severe interstitial nephritis (figure 1B). Immunohistochemistry for myoglobin pigment was positive in the tubular casts (figure 1C). Immunofluorescence was negative for immunoglobulins and complements. We initiated the patient on 1 mg/kg of prednisolone in view of interstitial nephritis. At week 6, the patient’s serum creatinine had decreased to 177 µmol/L. Steroids were tapered and stopped over next 4 weeks and the patient was advised not to take statins in future. Dual antiplatelet agents (DAPT) and lipid lowering agents like statin are crucial in the management of acute coronary syndrome (ACS). Guidelines recommend ticagrelor in combination with aspirin for prevention of stent thrombosis in patients with ACS.1 AKI due to statin is under recognised and probably under reported as patients who receive statins are generally elderly and have many confounding factors for renal dysfunction like diabetes, hypertension and atherosclerotic renovascular disease. In addition, they receive additional drugs like renin angiotensin blockers and diuretics that can also cause AKI. Renal biopsy is seldom done in these patients as they often receive antiplatelet agents.

Statin-induced rhabdomyolysis is a severe form of muscle damage associated with very high CK levels, with myoglobinuria and/or myoglobinemia with a concomitantly increased risk of renal failure. The risk of statin-related rhabdomyolysis is increased with increased statin dose, increased statin blood concentration, age greater than 75 years, female gender, low body mass index, hypothyroidism, chronic kidney disease and drug interactions with cytochrome P450 3A4 enzyme inhibitors.2 Among the statins, simvastatin and atorvastatin are mainly metabolised by CYP3A4 isoenzyme while rosuvastatin is metabolised by CYP2C9. Ticagrelor is metabolised by cytochrome P450 3A4, same as most of the statins and it competitively inhibits this enzyme leading to accumulation of statins metabolised by CYP 3A4. Besides inhibition of CYP3A4 isoenzymes, ticagrelor also has moderate activity for blood (2+) but no erythrocytes on microscopic examination. Further, she had an elevated creatine kinase (CK) level of 38 908 U/L (reference range 0–195 U/L) and urine myoglobin of 1073 ng/mL (reference range 28–72 ng/mL). Remaining work up including antinuclear antibody (ANA), anti-neutrophil cytoplasmic antibody (ANCA), serum protein electrophoresis and hepatitis serology were negative. The patient denied taking any other drug, including indigenous or over the counter medications. A clinical diagnosis of statin induced rhabdomyolysis was considered based on muscle cramps, brown coloured urine, elevated muscle enzymes and urine dipstick/microscopy dissociation. We stopped rosuvastatin on day 2 and substituted ticagrelor with clopidogrel. The patient was initiated on haemodialysis via a tunneled cuffed internal jugular catheter in view of oliguria. Gradually over next 1 week, the patient had improvement in the form of increase in urine output and declining CK levels. She was discharged after 1 week with serum creatinine of 530 µmol/L and haemodialysis was stopped. However, in view of non-resolving acute kidney injury (AKI), a kidney biopsy was done at week 4 that showed evidence of pigmented casts in the tubules and tubular injury with severe interstitial nephritis (figure 1B). Immunohistochemistry for myoglobin pigment was positive in the tubular casts (figure 1C). Immunofluorescence was negative for immunoglobulins and complements. We initiated the patient on 1 mg/kg of prednisolone in view of interstitial nephritis. At week 6, the patient’s serum creatinine had decreased to 177 µmol/L. Steroids were tapered and stopped over next 4 weeks and the patient was advised not to take statins in future. Dual antiplatelet agents (DAPT) and lipid lowering agents like statin are crucial in the management of acute coronary syndrome (ACS). Guidelines recommend ticagrelor in combination with aspirin for prevention of stent thrombosis in patients with ACS.1 AKI due to statin is under recognised and probably under reported as patients who receive statins are generally elderly and have many confounding factors for renal dysfunction like diabetes, hypertension and atherosclerotic renovascular disease. In addition, they receive additional drugs like renin angiotensin blockers and diuretics that can also cause AKI. Renal biopsy is seldom done in these patients as they often receive antiplatelet agents.

Statin-induced rhabdomyolysis is a severe form of muscle damage associated with very high CK levels, with myoglobinuria and/or myoglobinemia with a concomitantly increased risk of renal failure. The risk of statin-related rhabdomyolysis is increased with increased statin dose, increased statin blood concentration, age greater than 75 years, female gender, low body mass index, hypothyroidism, chronic kidney disease and drug interactions with cytochrome P450 3A4 enzyme inhibitors.2 Among the statins, simvastatin and atorvastatin are mainly metabolised by CYP3A4 isoenzyme while rosuvastatin is metabolised by CYP2C9. Ticagrelor is metabolised by cytochrome P450 3A4, same as most of the statins and it competitively inhibits this enzyme leading to accumulation of statins metabolised by CYP 3A4. Besides inhibition of CYP3A4 isoenzymes, ticagrelor also has moderate
CYP2C9-inhibiting properties in vitro. Apart from this, other potential mechanisms like inhibition of organic anion transporter polypeptides (OATPs) and P-glycoprotein (P-gp) has been also proposed for interaction between ticagrelor and statins. This drug interaction explains the increased risk of statin-related muscle toxicity with concomitant use of ticagrelor.

The prime suspect for AKI due to statins is rhabdomyolysis. However, the data from Jupiter study showed that only 0.01% of patients who received rosuvastatin 20 mg developed rhabdomyolysis while AKI was seen in 0.21% of patients. Thus, indicating that rhabdomyolysis does not account for AKI in all patients. Another possible mechanism is a direct or immune mediated acute or subacute tubulointerstitial nephritis (TIN). There is a published literature in which rosuvastatin caused AKI due to TIN which resolved after drug withdrawal and treatment with steroids. Our case is rare as the patient had developed both rhabdomyolysis as a possible rosuvastatin side effect potentiated by ticagrelor and statin-induced TIN. This case emphasises the role of kidney biopsy in cases of non-resolving AKI. Clinicians should be aware of the potential renal toxicity of statins especially at high doses. It is a good practice to measure CK before prescribing statin to identify those at potential risk of myopathy. One should be vigilant and routinely monitor renal function tests during the first few months after initiation of high dose statin.

**References**

2. Danielak D, Karazniewicz-Kada M, Głowka F. Assessment of the risk of rhabdomyolysis and myopathy during concomitant treatment with ticagrelor and statins. Drugs 2018;78:1105–12.

**ORCID ID**

Sachin Motiram Naik http://orcid.org/0000-0001-7429-613X

**Learning points**

- Careful drug history and naked eye urine examination should be performed in all cases of acute kidney injury (AKI).
- Combined use of statin and ticagrelor poses risk for rhabdomyolysis, especially in elderly.
- It is a good practice to measure creatine kinase (CK) before prescribing statin to identify those at potential risk of myopathy.
- Renal biopsy should be performed in cases of non-resolving AKI to identify potentially treatable causes.